Gonadotropin-Releasing Hormone Agonist for Preservation of Ovarian Function During (Neo)Adjuvant Chemotherapy for Breast Cancer

Reproductive Endocrinology, Department of Obstetrics and Gynecology, Rambam Health Care Campus, Rappaport Institute, Technion-Faculty of Medicine, Bath-Galim, Haifa, Israel, 31096
Journal of Clinical Oncology (Impact Factor: 18.43). 05/2012; 30(26):3310. DOI: 10.1200/JCO.2012.41.8467
Source: PubMed
Download full-text


Available from: Zeev Blumenfeld, Jan 25, 2016

  • No preview · Article · Sep 2012 · Journal of Clinical Oncology
  • [Show abstract] [Hide abstract]
    ABSTRACT: The protection of ovarian function during chemotherapy is an urgent issue to be resolved after the fertility preserving surgery on patients with ovarian cancer. The paper summarizes and analyzes the research progress on the protective measures in the aspects of gonadotropin releasing hormone analogue (GnRHa), cell protecting agents, and traditional Chinese medical science and drugs.
    No preview · Article · Nov 2014 · European journal of gynaecological oncology
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Introduction: The late effects of cancer treatment have recently gained a worldwide ubiquitous interest among reproductive endocrinologists, oncologists, and all health care providers. Despite many publications on this subject, there are many equivocal issues necessitating summary. The case for and against using GnRH-agonist for fertility preservation is summarized with the rationale that preventing ovarian failure may be better than treating it. Areas covered: We searched Medline in the last 10 years using terms: 'fertility preservation', 'female chemotherapy', 'Gonadotropin-releasing hormone (GnRH) analogues', 'GnRH agonists' 'gonadotoxicity', and 'cancer treatment'. We included mainly publications from the past 7 years, but did not exclude previous, commonly referenced publications. Here, we summarize the various methods available for fertility preservation and minimizing chemotherapy induced gonadotoxicity. Expert opinion: Until now, 20 studies (15 retrospective and 5 randomized controlled trial) have reported on 2038 patients treated with GnRH-a in parallel to chemotherapy, showing a significant decrease in premature ovarian failure (POF) rate in survivors versus 8 studies reporting on 509 patients, with negative results. Patients treated with GnRH-a in parallel to chemotherapy preserved their cyclic ovarian function in 91% of cases as compared to 41% of controls, with a pregnancy rate of 19 - 71% in the treated patients. Furthermore, over 10 recent meta-analyses have concluded that GnRH-a are beneficial and may decrease the risk of POF in survivors. Because most of the methods involving ovarian or egg cryopreservation are not yet clinically established and unequivocally successful, these young patients deserve to be informed with all the various modalities to minimize gonadal damage and preserve ovarian function and future fertility. Combining the various modalities for a specific patient may increase the odds of preservation of future fertility.
    Full-text · Article · Mar 2015 · Expert Opinion on Pharmacotherapy